Opko Health Inc
$ 1.18
0.85%
15 Apr - close price
- Market Cap 898,210,000 USD
- Current Price $ 1.18
- High / Low $ 1.19 / 1.16
- Stock P/E N/A
- Book Value 1.67
- EPS -0.30
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.17 %
- 52 Week High 1.60
- 52 Week Low 1.09
About
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
Analyst Target Price
$3.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-07-31 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 | 2023-05-03 |
| Reported EPS | -0.0358 | 0.03 | -0.19 | -0.0949 | 0.01 | -0.03 | -0.01 | -0.12 | -0.09 | -0.11 | -0.03 | -0.02 |
| Estimated EPS | -0.0671 | -0.06 | -0.1133 | -0.11 | -0.1 | -0.09 | -0.09 | -0.09 | -0.09 | -0.1 | -0.07 | -0.08 |
| Surprise | 0.0313 | 0.09 | -0.0767 | 0.0151 | 0.11 | 0.06 | 0.08 | -0.03 | 0 | -0.01 | 0.04 | 0.06 |
| Surprise Percentage | 46.6468% | 150% | -67.6964% | 13.7273% | 110% | 66.6667% | 88.8889% | -33.3333% | 0% | -10% | 57.1429% | 75% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OPK
2026-04-14 10:11:05
OPKO Health, Inc. is advancing its COVID-19 prevention treatment, MDX2301, a tetravalent bispecific antibody with potential to neutralize all known SARS-CoV-2 variants. The company has completed a Phase 1 trial funded by federal grants, evaluating safety and tolerability. H.C. Wainwright maintains a "Buy" rating and a $3 price target, expecting positive pharmacokinetic and immunogenicity data by year-end, underscoring optimism for MDX2301's broad and durable protection capabilities.
2026-04-13 22:09:44
This article identifies top healthcare penny stocks favored by hedge funds. It highlights OPKO Health, Inc. (NASDAQ:OPK) as one of the best picks, noting its significant upside potential and ongoing work on a promising COVID-19 prevention treatment. H.C. Wainwright reiterated a Buy rating and a $3 price target for OPK, based on its Phase 1 trial results for MDX2301 and its broad neutralization potential against SARS-CoV-2 variants.
2026-04-13 19:41:06
This Simply Wall St analysis provides a detailed look into OPKO Health (Nasdaq:OPK), highlighting its current market valuation, future growth prospects, and financial health. The report indicates the stock is currently trading below its estimated fair value, with key takeaways focusing on its diversified pipeline, strategic partnerships, and recent financial updates. Despite being unprofitable, the company has several encouraging developments and analyst insights on its diagnostic and pharmaceutical segments.
2026-04-11 11:10:18
OPKO Health (NASDAQ:OPK) has received an average 'Hold' recommendation from analysts, with ratings ranging from 'Sell' to 'Strong Buy' and an average 12-month price target of $1.55. This mixed outlook reflects the challenges faced by the diversified healthcare company in its core business segments. Investors are advised to carefully evaluate the company's long-term potential amid ongoing uncertainties in the healthcare industry.
2026-04-11 08:09:08
Analysts have given OPKO Health (NASDAQ:OPK) an average "Hold" rating, with a consensus 12-month price target of $1.55. Despite beating quarterly EPS and revenue estimates, the company reported a negative net margin and a 19.1% year-over-year revenue decline. Institutional ownership remains high at 64.63%, with major funds increasing their stakes in the biotechnology company.
2026-04-08 19:11:05
OPKO Health's ModeX Therapeutics has initiated a Phase 1 clinical trial for MDX2301, a multispecific antibody designed for the prevention of COVID-19. This tetravalent bispecific antibody aims to neutralize all known SARS-CoV-2 variants and is being evaluated for safety and tolerability in healthy volunteers and high-risk adults. The study, funded by the U.S. Department of Health and Human Services (HHS) ASPR/BARDA, represents a significant step in developing broad and durable protection against the evolving virus.
